Creative Biolabs Unveils Cutting-Edge SARS-CoV-2 In Vitro Diagnostic Solutions

February 27
15:48 2024
With a dedicated team possessing a rich interdisciplinary background in infectious diseases and molecular technologies, Creative Biolabs provides global clients with top-tier services in SARS-CoV-2 testing, vaccine development, and drug research.

New York, USA – February 27, 2024 – The imperative of accurate and swift virus detection has long been underscored in the realm of infectious disease management. Presently, Creative Biolabs has refined and augmented its existing SARS-CoV-2 in vitro diagnostics (IVD) technology, culminating in a robust and precise testing solution tailored for the novel coronavirus.

“Our suite of services encompasses a diverse array of technologies, including reverse transcription polymerase chain reaction (RT-PCR for SARS-CoV-2), rRT-PCR, and RT-LAMP. This comprehensive approach spans the gamut from molecular detection system development to the creation of novel ready-to-use reagent kits for IVD, adeptly meeting the multifaceted research and development needs of our global clientele,” elucidated a molecular expert at Creative Biolabs.

Tailored SARS-CoV-2 diagnostic molecular development services are executed through a systematic approach within Creative Biolabs’ expert-integrated solutions:

* Primer and probe design: Crafting highly specific primers and probes tailored to customer requirements and virus characteristics to ensure the precision and sensitivity of the detection scheme.

* Prototype testing and optimization: Offering prototype testing services to clients and fine-tuning the detection scheme based on test results to optimize its performance.

* Stability research and optimization: Undertaking rigorous stability research on the developed detection system to ensure its resilience and dependability across diverse environmental conditions.

* Assay validation and confirmation: Methodically validating the developed detection system to ensure alignment with quality standards and regulatory requisites, thereby ensuring its reliability in clinical practice.

“In addition to RT-PCR, our repertoire extends to encompass supplementary SARS-CoV-2 RNA imaging services, leveraging RNA aptamer-Lemon to devise high-affinity, highly specific RNA imaging tools, furnishing a dependable solution for the quantification and localization of viral RNA.”

In tandem with the widespread havoc wrought by the COVID-19 pandemic, Creative Biolabs is concurrently spearheading research and development efforts in preventive anti-SARS-CoV-2 vaccines. “Our vaccine development initiatives at Creative Biolabs span the gamut from target identification and immune response analysis to the evaluation of infection models. Processes such as subunit vaccines, in silico vaccines for SARS-CoV-2, analysis and qualification services, and formulation optimization solutions can all be seamlessly conducted on our platform.”

For those seeking professional support in their SARS-CoV-2 research endeavors, please visit

About Creative Biolabs

With a seasoned scientific team and state-of-the-art technology platforms, Creative Biolabs ensures that its SARS-CoV-2 in vitro diagnostic solutions attain the pinnacle of performance in sensitivity, reproducibility, accuracy, inhibitor tolerance, and specificity through rigorous quality control and technical validation.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States